Bristol-Myers Squibb (BMS) and bluebird bio announced that the Food and Drug Administration (FDA) has approved the marketing of Abecma (idecabtagene vicleucel), a chimeric antigen receptor T (CAR-T) cell immunotherapy targeting BRead More…
On July 9th, Fate Therapeutics announced that U.S. Food and Drug Administration has approved the first IND application for iPSC-derived allogeneic CAR-T cell therapy FT819 for the treatment of recurrent/refractory B-cell malignant tumors,Read More…
A recently published report summarizes the biomarker targets in both hematological and solid malignancies for CAR T cell therapy and discusses potential new biomarker target. A biomarker is an integral part ofRead More…
Recently, MaxCyte announced that the company’s chimeric antigen receptor (CAR) cell therapy for the treatment of solid tumors based on non-viral messenger RNA (mRNA) technology has been approved by the Food andRead More…
There is no doubt that the emergence of immunotherapy has redefined the field of cancer treatment as breakthrough progress. Most immunotherapies now focus on the adaptive immune response, that is, on TRead More…
On February 1, NEJM, the top medical journal, published the results of a pivotal multi-center critical phase 2 trial in support of the “first CAR-T therapy Tisagenlecleucel listed”. The overall survival of patientsRead More…